Drug Trial Radar · NCT05876312
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 7, 2023
Primary completion
Mar 31, 2028
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- ADARx Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ADARx Australia Pty Ltd; Novotech (Australia) Pty Limited
- First posted
- May 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
ADX-038Drug
siRNA duplex oligonucleotide
PlaceboDrug
Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety in Healthy VolunteersTime frame: 365 days
- Safety in Paroxysmal Nocturnal Hemoglobinuria ParticipantsTime frame: 365 days
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Nucleus Network Brisbane
Brisbane, Queensland, Australia · Completed
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Completed
Royal Melbourne Hospital
Parkville, Victoria, Australia · Recruiting
Richmond Pharmacology Ltd
London, London, United Kingdom · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.